Home/Filings/4/0001179110-09-012853
4//SEC Filing

Dinerstein Robert C 4

Accession 0001179110-09-012853

CIK 0000874255other

Filed

Sep 2, 8:00 PM ET

Accepted

Sep 3, 3:59 PM ET

Size

17.6 KB

Accession

0001179110-09-012853

Insider Transaction Report

Form 4
Period: 2009-09-01
Transactions
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2009-09-01$16.00/sh30,000$480,0000 total
    Exercise: $10.75Exp: 2016-09-12Common Stock (30,000 underlying)
  • Disposition to Issuer

    Restricted Stock Units

    2009-09-01$16.00/sh6,721$107,5360 total
    Common Stock (6,721 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2009-09-01$16.00/sh18,000$288,0000 total
    Exercise: $3.72Exp: 2019-03-04Common Stock (18,000 underlying)
  • Disposition to Issuer

    Restricted Stock Units

    2009-09-01$16.00/sh3,161$50,5760 total
    Common Stock (3,161 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2009-09-01$16.00/sh18,000$288,0000 total
    Exercise: $7.91Exp: 2018-05-14Common Stock (18,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2009-09-01$16.00/sh18,000$288,0000 total
    Exercise: $14.92Exp: 2017-05-16Common Stock (18,000 underlying)
Footnotes (8)
  • [F1]This option was canceled in the merger in exchange for a cash payment of $19,530.00, representing the difference between the exercise price of the option and thmerger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
  • [F2]This option was canceled in the merger in exchange for a cash payment of $157,650.00, representing the difference between the exercise price of the option and thmerger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
  • [F3]This option was canceled in the merger in exchange for a cash payment of $145,620.00, representing the difference between the exercise price of the option and thmerger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
  • [F4]This option was canceled in the merger in exchange for a cash payment of $221,040.00, representing the difference between the exercise price of the option and thmerger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
  • [F5]Each restricted stock unit reprsents a contingent righ to receive one (1) share of Medarex, Inc. common stock.
  • [F6]The Restricted Stock Units vested ratably on each of the first, second and third anniversaries of the grant date and the receipt of the shares of common stock was deferred until the individual's retirement or separation of service from the Board.
  • [F7]This Restricted Stock Unit was canceled in the merger in exchange for a cash payment of $50,576.00, based on the merger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
  • [F8]This Restricted Stock Unit was canceled in the merger in exchange for a cash payment of $107,536.00, based on the merger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.

Issuer

MEDAREX INC

CIK 0000874255

Entity typeother

Related Parties

1
  • filerCIK 0001375535

Filing Metadata

Form type
4
Filed
Sep 2, 8:00 PM ET
Accepted
Sep 3, 3:59 PM ET
Size
17.6 KB